Tag : ASTHMA EXACERBATION

A post hoc responder analysis of the integrated SWIFT/AGILE studies demonstrated that twice-yearly depemokimab maintained clinically meaningful responses over 2 years in patients with uncontrolled asthma symptoms at baseline. Responses were sustained across exacerbations, St. George’s Respiratory Questionnaire (SGRQ) and Asthma Control Questionnaire-5 (ACQ-5), with greater increase following the switch from placebo to depemokimab.

The anti-interleukin-5 receptor α (anti-IL-5α) monoclonal antibody (mAb), benralizumab, had been approved for the treatment of severe eosinophilic asthma offering significant improvements in exacerbation rates, maintenance oral corticosteroid (mOCS) use, and other asthma outcomes in phase 3 clinical trials. Although benralizumab has achieved asthma remission in clinical trials and non-United States (US) populations, real-world data within the US assessing similar outcomes remained limited.
